DexCom, Inc. vs Energy Select Sector SPDR Fund — how do they compare? DexCom, Inc. trades at $77.89 (market cap $28.06B), while Energy Select Sector SPDR Fund trades at $57.05. Which is the better fit depends on your goals.
| DXCM | XLE | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $62.57 |
52-Week Low | $54.84 | $42.12 |
Enterprise Value | $27.03B | — |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
XLE trades at $57.065, up 0.2% today, with a bullish technical signal from moving averages and strong support at $56. The ETF has gained 21% year-to-date, ranking among top-performing sector SPDRs. Recent news highlights energy sector strength from data center demand and geopolitical tensions, while a dividend of $0.38 is scheduled for June 2026.
Outlook remains positive due to sector earnings growth and oil price stability, but risks include volatile crude markets and competitive pressure from clean energy. Analyst sentiment is mixed, with technical indicators showing overbought conditions near-term.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →